Tel.:
+34 91 736 2385
LOCAL TIME
Contact:
Katarina Gluic
Hours:
Mon-Thu 8:30-17:00 Fri 8:30-15:00
07:44
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments
WFH 2016 World Congress
24-28 July 2016 Orlando
About us
FAQs
Help Line
Personal Area
Homepage
Discussion forum -
WFH 2016 World Congress
Topic -
Acquired coagulation disorders
If you are already registered in PosterSessionOnline, enter your e-mail and click on LOGIN. Otherwise click on REGISTER
Thread / Poster
Author
Replies
Last reply
NovoSeven(R) in the treatment of acquired haemophilia A: Results from the prospective study (ACQUI-7) in France
Hélène Schneid
1
7/21/2016 1:39:00 PM
Management of acquired hemophilia: a single center experience.
Eva Ivanová
1
7/20/2016 3:07:00 PM
Diagnosis of von Willebrand disease in population of Western Mexico
María Guadalupe
1
7/7/2016 11:45:00 PM
Acquired Von Willebrand Syndrome: Mechanisms and response to treatment
Pu-Lin Luo
1
7/7/2016 11:23:00 PM
Anti-FVIII IgG1 titers correlate with Bethesda levels in patients with acquired hemophilia
Elizabeth Donnachie
1
7/7/2016 2:37:00 PM
FVIII activity of OBIZUR can be measured in hemophilic plasma with standard FVIII one-stage clotting assays
Peter L.
1
7/7/2016 12:45:00 PM
Hypofibrinogenemia as the first sign of autoimmune disease
Erica Okazaki
1
7/6/2016 8:18:00 PM
Acquired haemophilia A in a Jehovahs Witness
Jacek Trelinski
1
7/5/2016 3:03:00 PM
Most viewed poster for this congress
Poster:
13
Visits:
590
Title:
Algorithmic evidence-based phenotype screening and collaborative approach to attacking symptoms of nonadherence in patients with bleeding disorders
Authors:
Jay Bryant-Wimp , Jay Bryant-Wimp, RPh
Centre:
Integrite Solutions
Poster most viewed in this topic
Poster:
1
Visits:
68
Title:
Acquired Von Willebrand Syndrome: Mechanisms and response to treatment
Authors:
Pu-Lin Luo , Pu-Lin Luo
Centre:
Guys and St Thomas Hospital
About us
Terms and Conditions
Special Access
Commercial Web Access
Follow us on: